Ieq Capital LLC Buys Shares of 10,859 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Ieq Capital LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,859 shares of the company’s stock, valued at approximately $193,000.

Several other institutional investors and hedge funds also recently bought and sold shares of TARS. Cowen AND Company LLC purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $36,129,000. BlackRock Inc. grew its stake in Tarsus Pharmaceuticals by 51.0% during the 2nd quarter. BlackRock Inc. now owns 2,199,753 shares of the company’s stock valued at $39,750,000 after acquiring an additional 742,493 shares in the last quarter. Vanguard Group Inc. grew its stake in Tarsus Pharmaceuticals by 42.7% during the 3rd quarter. Vanguard Group Inc. now owns 935,649 shares of the company’s stock valued at $16,018,000 after acquiring an additional 279,826 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Tarsus Pharmaceuticals by 2,784.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 245,972 shares of the company’s stock valued at $4,371,000 after acquiring an additional 237,445 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $3,520,000. Hedge funds and other institutional investors own 70.02% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ TARS opened at $27.24 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.15 and a quick ratio of 11.15. The business has a 50 day simple moving average of $20.49 and a 200 day simple moving average of $18.15. Tarsus Pharmaceuticals, Inc. has a 52 week low of $11.33 and a 52 week high of $29.01.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last announced its earnings results on Thursday, November 9th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.12. The company had revenue of $1.87 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on TARS shares. The Goldman Sachs Group began coverage on Tarsus Pharmaceuticals in a research note on Monday, November 20th. They set a “neutral” rating and a $19.00 target price on the stock. Lifesci Capital reissued an “outperform” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, December 26th. Finally, HC Wainwright boosted their price target on Tarsus Pharmaceuticals from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, November 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

View Our Latest Analysis on TARS

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 8,356 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $16.31, for a total transaction of $136,286.36. Following the completion of the transaction, the general counsel now directly owns 31,966 shares in the company, valued at $521,365.46. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Bobak R. Azamian sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $20.22, for a total transaction of $161,760.00. Following the completion of the transaction, the chief executive officer now directly owns 830,106 shares in the company, valued at $16,784,743.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Bryan Wahl sold 8,356 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $16.31, for a total value of $136,286.36. Following the transaction, the general counsel now owns 31,966 shares of the company’s stock, valued at $521,365.46. The disclosure for this sale can be found here. Insiders sold a total of 66,963 shares of company stock worth $1,290,156 over the last three months. 11.54% of the stock is currently owned by insiders.

About Tarsus Pharmaceuticals

(Free Report)

Tarsus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report).

Institutional Ownership by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.